Gracell Biotechnologies Stock Working Capital

Gracell Biotechnologies fundamentals help investors to digest information that contributes to Gracell Biotechnologies' financial success or failures. It also enables traders to predict the movement of Gracell Stock. The fundamental analysis module provides a way to measure Gracell Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gracell Biotechnologies stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gracell Biotechnologies Company Working Capital Analysis

Gracell Biotechnologies' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Gracell Biotechnologies Working Capital

    
  1.28 B  
Most of Gracell Biotechnologies' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gracell Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

According to the company's disclosures, Gracell Biotechnologies has a Working Capital of 1.28 B. This is 199.57% higher than that of the Biotechnology sector and 136.74% higher than that of the Health Care industry. The working capital for all United States stocks is 13.74% higher than that of the company.

Gracell Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gracell Biotechnologies' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics of similar companies.
Gracell Biotechnologies is currently under evaluation in working capital category among its peers.

Gracell Fundamentals

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Gracell Stock

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk